Encore warns of loss on reorganisation
This article was originally published in Clinica
Executive Summary
US orthopaedics company Encore Medical says that a reorganisation of its sales and marketing department, as well as rationalisation of its product line, will mean a loss for the company in the fourth quarter and for the full year. However, the Austin, Texas company says that the short-term costs involved in the reorganisation will not deter Encore from attempting to grow by acquisition.
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.